* Cytek Biosciences Inc CTKB.OQ reported a quarterly
adjusted
loss of 8 cents per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of 1 cents. The mean expectation of five analysts for the
quarter was for a loss of 3 cents per share. Wall Street
expected results to range from -4 cents to -2 cents per share.
* Revenue fell 6.2% to $46.62 million from a year ago;
analysts
expected $49.53 million.
* Cytek Biosciences Inc's reported EPS for the quarter was a
loss
of 8 cents.
* The company reported a quarterly loss of $10.43 million.
* Cytek Biosciences Inc shares had risen by 0.7% this
quarter and
lost 38.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 15.4%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Cytek Biosciences
Inc is $9.00
This summary was machine generated from LSEG data August 7 at
09:45 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.03 -0.08 Missed
Mar. 31 2024 -0.04 -0.05 Missed
Dec. 31 2023 0.00 0.04 Beat
Sep. 30 2023 0.03 0.00 Missed